Gigantol isomer-1

MedChemExpress

| Cat. No.: | HY-N2523 | | |
|--------------------|--|-------|----------|
| CAS No.: | 67884-30-4 | | |
| Molecular Formula: | C ₁₆ H ₁₈ O ₄ | | |
| Molecular Weight: | 274.31 | | |
| Target: | Wnt | | |
| Pathway: | Stem Cell/Wnt | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

®

SOLVENT & SOLUBILITY

| In Vitro | DMSO : ≥ 100 mg/mL (364.55 mM) Ethanol : 50 mg/mL (182.28 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. | | | | | |
|------------------------------|---|---|-----------|------------|------------|--|
| Preparing Stock Solutions | | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | |
| | Preparing Stock Solutions | 1 mM | 3.6455 mL | 18.2276 mL | 36.4551 mL | |
| | | 5 mM | 0.7291 mL | 3.6455 mL | 7.2910 mL | |
| | | 10 mM | 0.3646 mL | 1.8228 mL | 3.6455 mL | |
| | Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution | | | | | |
| | 3. Add each solvent o Solubility: ≥ 2.5 mg | one by one: 10% DMSO >> 90% cor g/mL (9.11 mM); Clear solution | n oil | | | |

| BIOLOGICAL ACTIVITY | | | |
|---------------------------|---|--|--|
| Description | Gigantol isomer-1 is a bibenzyl compound derived from Dendrobium nobile. Gigantol isomer-1 shows promising therapeutic potential against cancer cells. Gigantol isomer-1 is a novel inhibitor of the Wnt/β-catenin pathway. | | |
| IC ₅₀ & Target | Wnt ^[1] | | |

Ο

ÓН

<u>_</u>0_

ΟН

| In Vitro | Gigantol isomer-1 decreases the level of phosphorylated LRP6 and cytosolic β -catenin in HEK293 cells. In breast cancer MDA-MB-231 and MDA-MB-468 cells, treatment with Gigantol isomer-1 reduces the level of phosphorylated LRP6 ^[1] . Gigantol isomer-1 significantly inhibits the proliferation and induces apoptosis of the HepG2 cells. Gigantol isomer-1 at concentrations of 1, 40 and 150 μ M markedly decreases the cell viability by 11.7, 30.0 and 56.4% at 24 h and 21.1, 66.8 and 85.5% at 48 h, respectively. The IC ₅₀ value is 9.30 μ M ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
|----------|---|
| In Vivo | LDD and Gigantol isomer-1 (25–100 mg/kg, p.o.) significantly increase the hot-plate latency in comparison to vehicle-treated mice and decreased carrageenaninduced inflammation in rats ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| PROTOCOL | |
|---|--|
| Cell Assay ^[2] | , HepG2 cells are treated with a series of concentrations of Gigantol (1, 10, 40, 80 and 150 μM) for different time intervals (12, 24 and 48 h). The cytotoxicity is measured using MTT assays ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Animal Administration ^[3] | Rats ^[3] The anti-inflammatory activity is determined by carrageenan-induced edema test in the hind paws of rats. Sprague-Dawley rats are fasted for 15 h before the experiment with free access to water. One hundred microlitres of 1% carrageenan (10 mg/mL, Type IV, lambda) suspension is prepared 30 min before each experiment and injected into the plantar side of right hindpaw of the rats. The CH2Cl2-MeOH Scaphyglottis livida and Maxillaria densa extracts (150-600 mg/kg), as well as compound LDD and gigantol (25-100 mg/kg), are orally administered. The extracts, LDD and gigantol are administered 1 h before the carrageenan treatment ^[3] .Mice ^[3] Mice receive an oral administration of vehicle (0.2% Tween-80) or increasing doses of Scaphyglottis livida and Maxillaria densa extracts (150-600 mg/kg) or LDD and gigantol (25-100 mg/kg) 30 min before the thermal noxious stimuli in the hot- plate test. Morphine (1.5-6 mg/kg, p.o.) is used as positive control. Mice are observed before and at 30, 60, 90 and 120 min |
| | after drugs administration ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

• Oncotargets Ther. 2020 Nov 4;13:11337-11346.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Yu S, et al. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells. BMC Complement Altern Med. 2018 Feb 14;18(1):59.

[2]. Chen H, et al. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 2017 Feb;37(2):865-870.

[3]. Déciga-Campos M, et al. Antinociceptive and anti-inflammatory effects of compounds isolated from Scaphyglottis livida and Maxillaria densa. J Ethnopharmacol. 2007 Nov 1;114(2):161-8.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA